Market closed
Rocket Pharmaceuticals/$RCKT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Rocket Pharmaceuticals
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Ticker
$RCKT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
268
Website
RCKT Metrics
BasicAdvanced
$1B
Market cap
-
P/E ratio
-$2.75
EPS
1.09
Beta
-
Dividend rate
Price and volume
Market cap
$1B
Beta
1.09
52-week high
$32.53
52-week low
$11.28
Average daily volume
1.2M
Financial strength
Current ratio
6.047
Quick ratio
5.894
Long term debt to equity
6.912
Total debt to equity
7.776
Interest coverage (TTM)
-145.40%
Management effectiveness
Return on assets (TTM)
-34.48%
Return on equity (TTM)
-59.27%
Valuation
Price to book
3.14
Price to tangible book (TTM)
3.9
Price to free cash flow (TTM)
-5.261
Growth
Earnings per share change (TTM)
-13.14%
3-year earnings per share growth (CAGR)
-3.21%
What the Analysts think about RCKT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Rocket Pharmaceuticals stock.
RCKT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RCKT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RCKT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Rocket Pharmaceuticals stock?
Rocket Pharmaceuticals (RCKT) has a market cap of $1B as of December 21, 2024.
What is the P/E ratio for Rocket Pharmaceuticals stock?
The price to earnings (P/E) ratio for Rocket Pharmaceuticals (RCKT) stock is 0 as of December 21, 2024.
Does Rocket Pharmaceuticals stock pay dividends?
No, Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Rocket Pharmaceuticals dividend payment date?
Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders.
What is the beta indicator for Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.